Alliancebernstein L.P. Has $184.89 Million Stake in Insmed, Inc. $INSM

Key Points

• Alliancebernstein L.P. increased its stake in Insmed, Inc. by 2.5% in Q1, holding 2,423,513 shares valued at approximately $184.89 million as of the quarter's end.
• Insmed reported a quarterly EPS of ($1.70), missing estimates, but had a revenue of $107.42 million, which surpassed expectations.
• Numerous analysts have raised their price targets for Insmed, with Wells Fargo & Company increasing theirs from $140.00 to $171.00 and giving the stock an "overweight" rating.

Alliancebernstein L.P. raised its position in Insmed, Inc. (NASDAQ:INSM - Free Report) by 2.5% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,423,513 shares of the biopharmaceutical company's stock after buying an additional 59,952 shares during the quarter. Alliancebernstein L.P. owned about 1.33% of Insmed worth $184,890,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of INSM. Cullen Frost Bankers Inc. increased its holdings in Insmed by 164.9% in the 1st quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company's stock valued at $27,000 after buying an additional 221 shares during the period. Elequin Capital LP bought a new position in Insmed in the 4th quarter valued at about $28,000. NBC Securities Inc. bought a new position in Insmed in the 1st quarter valued at about $49,000. Versant Capital Management Inc increased its holdings in Insmed by 546.3% in the 1st quarter. Versant Capital Management Inc now owns 698 shares of the biopharmaceutical company's stock valued at $53,000 after buying an additional 590 shares during the period. Finally, Signaturefd LLC increased its holdings in Insmed by 60.0% in the 1st quarter. Signaturefd LLC now owns 867 shares of the biopharmaceutical company's stock valued at $66,000 after buying an additional 325 shares during the period.

Insmed Price Performance

Shares of INSM traded down $1.63 during mid-day trading on Wednesday, reaching $145.57. The company had a trading volume of 348,567 shares, compared to its average volume of 2,773,972. The company's 50 day simple moving average is $116.55 and its 200 day simple moving average is $90.60. Insmed, Inc. has a 1-year low of $60.40 and a 1-year high of $149.08. The company has a debt-to-equity ratio of 0.45, a quick ratio of 6.33 and a current ratio of 6.68. The company has a market capitalization of $30.77 billion, a price-to-earnings ratio of -25.51 and a beta of 0.97.

Insmed (NASDAQ:INSM - Get Free Report) last posted its earnings results on Thursday, August 7th. The biopharmaceutical company reported ($1.70) EPS for the quarter, missing the consensus estimate of ($1.30) by ($0.40). Insmed had a negative return on equity of 195.37% and a negative net margin of 259.82%.The business had revenue of $107.42 million for the quarter, compared to analyst estimates of $104.06 million. During the same quarter in the prior year, the business earned ($1.94) earnings per share. The firm's quarterly revenue was up 18.9% on a year-over-year basis. Insmed has set its FY 2025 guidance at EPS. Analysts expect that Insmed, Inc. will post -4.56 EPS for the current year.

Insider Buying and Selling at Insmed

In related news, COO Roger Adsett sold 25,000 shares of Insmed stock in a transaction that occurred on Tuesday, August 19th. The shares were sold at an average price of $127.58, for a total transaction of $3,189,500.00. Following the sale, the chief operating officer directly owned 105,637 shares in the company, valued at $13,477,168.46. This trade represents a 19.14% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Melvin Md Sharoky sold 10,000 shares of Insmed stock in a transaction that occurred on Wednesday, August 20th. The stock was sold at an average price of $129.50, for a total transaction of $1,295,000.00. Following the sale, the director owned 274,516 shares in the company, valued at approximately $35,549,822. This represents a 3.51% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 378,382 shares of company stock worth $40,169,038 over the last quarter. Insiders own 3.00% of the company's stock.

Analyst Ratings Changes

Several research firms have commented on INSM. HC Wainwright raised their target price on shares of Insmed from $90.00 to $120.00 and gave the company a "buy" rating in a report on Wednesday, June 11th. The Goldman Sachs Group raised their price target on shares of Insmed from $114.00 to $142.00 and gave the company a "buy" rating in a research note on Wednesday, August 13th. Bank of America raised their price target on shares of Insmed from $94.00 to $109.00 and gave the company a "buy" rating in a research note on Wednesday, June 11th. Leerink Partners raised their price target on shares of Insmed from $100.00 to $115.00 and gave the company an "outperform" rating in a research note on Tuesday, June 10th. Finally, Royal Bank Of Canada raised their price target on shares of Insmed from $108.00 to $120.00 and gave the company an "outperform" rating in a research note on Friday, August 8th. Sixteen investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, Insmed presently has an average rating of "Moderate Buy" and an average price target of $139.86.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.